Pathogenic role of advanced glycation end-products (AGEs): An overview

Peritoneal Dialysis International

Volumn 19, Issue SUPPL. 2, 1999, Pages

  Weiss, Miriam F ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Advanced glycation end products; AGEs; CML; N (carboxymethyl)lysine; Pentosidine; Peritoneal transport of AGEs

Indexed keywords

ADVANCED GLYCATION END PRODUCT; LYSINE DERIVATIVE; PENTOSIDINE;

CONFERENCE PAPER; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PRIORITY JOURNAL;

EID: 0033402631     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089901902s08     Document Type: Conference Paper

References (60)

1. Held P, Port F, Webb R, Wolfe RA, Bloembergen W, Turenne M, et al. Excerpts from United States Renal Data System 1996 Annual Data Report. Am J Kidney Dis. 1996; 28(Suppl 2):S1-165.
2. Agodoa L, Held PJ, Port FK. United States Renal Data System, USRDS 1995 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. Am J Kidney Dis. 1995; 26:(Suppl 2).
3. Vanholder R, Ringoir S. Infectious morbidity and defects of phagocytic function in end-stage renal disease: A Review. J Am Soc Nephrol. 1993; 3:1541-54.
4. Vlassara H. Serum advanced glycosylation end-products: A new class of uremic toxins? Blood Purif. 1994; 12:54-9.
5. Ritz E, Deppisch R, Nawroth P. Toxicity of uraemia -Does it come of AGE? Nephrol Dial Transplant. 1994; 9:1-2.
6. Sell DR, Monnier VM. End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest. 1990; 85:380-4.
7. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, et al. Advanced glycosylation end-products in patients with diabetic nephropathy. N Engl J Med. 1991; 325:836-42.
8. Monnier VM, Sell DR, Miyata S, Nagaraj RH, Odetti P, Lapolla A. Advanced Maillard reaction products as markers for tissue damage in diabetes and uraemia: Relevance to diabetic nephropathy. Acta Diabetol. 1992; 29:130-5.
9. Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM, et al. Reactive glycosylation endproducts in diabetic uremia and treatment of renal failure. Lancet. 1994; 343:1519-22.
10. Friedlander M, Wu Y, Schulak J, Monnier V, Hricik D. Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease. Am J Kidney Dis. 1995; 25:445-51.
11. Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurakawa K, et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end stage renal failure: Renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol. 1996; 7:1198-206.
12. Wolff S, Jiang Z, Hunt J. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med. 1991; 10:339-52.
13. Thornalley PJ. Advanced glycation and the development of diabetic complications. Unifying the involvement of glucose, methylglyoxal and oxidative stress. Baillieres Clin Endocrinol Metab. 1996; 3:146-66.
14. Miyata T, Wada Y, Cal Z, Iida Y, Horie K, Yasuda Y, et al. Implication of an increased oxidative stress in the formation of advanced glycation end-products in patients with end stage renal failure. Kidney Int. 1997; 51:1170-81.
15. Friedlander M, Wu Y, Randle C, Baumgardner G, DeOreo P, Monnier V, eds. Increased formation of pentosidine and Ne-(carboxymethyl)lysine in end stage renal disease: Role of dialysis clearance. In: O'Brien J, Nursten HE, Crabbe MJC, Ames JM, eds. The Maillard Reaction in Foods and Medicine. London: Royal Society of Chemistry; 1998:339-44.
16. Fu M, Requena J, JenkinsA, Lyons T, Baynes J, Thorpe S. The advanced glycation end product, Nε-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem. 1996; 271:9982-6.
17. Anderson M, Hazen S, Hsu F, Heinecke J. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycoaldehyde, 2-hydroxypropanal and acrolein: A mechanism for the generation of highly reactive α-hydroxy and α,β-unsaturated aldehydes by phagocytes at sites of inflammation. J Clin Invest. 1997; 99:397-403.
18. Baynes J. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991; 40:405-12.
19. Ahmed M, Thorpe S, Baynes J. Identification of Nε-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem. 1986; 261:4889-94.
20. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem. 1991; 266:11654-60.
21. Grandhee S, Monnier V. Mechanism of formation of the Maillard protein cross-link pentosidine. J Biol Chem. 1991; 266:11649-53.
22. Jontofsohn R, Trivisas G, Katz N, Kluthe R. Amino acid content of erythrocytes and plasma in uremia. Am J Clin Nutr. 1978; 31:1956-60.
23. Halliwell B, Gutteridge J. Role of free radicals and catalytic metal ions in human diseases: An overview. Methods Enzymol. 1990; 186:1-85.
24. Niwa T, Takeda N, Miyazaki T, Yoshizumi H, Tatematsu A, Maeda K, et al. Elevated serum levels of 3-deoxyglucosone, a potent protein-cross-linking intermediate of the Maillard reaction, in uremic patients. Nephron. 1995; 69:438-43.
25. Friedlander M, Wu Y, Elgawish A, Monnier V. Early and advanced glycosylation end-products: Kinetics of formation and clearance in peritoneal dialysis. J Clin Invest. 1996; 97:728-35.
26. Roselaar S, Nazhat N, Winyard P, Jones P, Cunningham J, Blake D. Detection of oxidants in uremic plasma by electron spin resonance spectroscopy. Kidney Int. 1995; 48:199-206.
27. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen A, Zingraff J, et al. Advanced oxidative protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996; 49:1304-13.
28. Itabe H, Yamamoto H, Imanaka T, Shinamura K, Uchiyama H, Kimura J, et al. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res. 1996; 37:45-53.
29. Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G, et al. Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis? Kidney Int. 1994; 45:876-83.
30. Ponka A, Kuhlback B. Serum ascorbic acid in patients undergoing chronic hemodialysis. Acta Med Scand. 1983; 213:305-7.
31. Loughrey C, Young I, Lightbody J, McMaster D, McNamee P, Trimbel E. Oxidative stress in hemodialysis. Q J Med. 1994; 87:679-83.
32. Cohen J, Viljoen M, Clifford D, DeOliveria A, Veriava Y, Milne F. Plasma vitamin E levels in chronically hemolyzing group of dialysis patients. Clin Nephrol. 1986; 25:42-7.
33. Ueda Y, Miyata T, Hashimoto T, Yamada H, Izuhara Y, Sakai H, et al. Implication of altered redox regulation by antioxidant enzymes in the increased plasma pentosidine, an advanced glycation end product, in uremia. Biochem Biophys Res Commun. 1998; 245:785-90.
34. Miyata T, Maeda K, Kurokawa K, van Ypersele de Strihou C. Oxidation conspires with glycation to generate noxious advanced glycation end-products in renal failure. Nephrol Dial Transplant. 1997; 12:255-8.
35. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, et al. Modification of LDL by advanced glycosylation end-products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A. 1994; 91:9441-5.
36. Steinberg D. Role of oxidized LDL and antioxidants in atherosclerosis. Adv Exp Med Biol. 1995; 369:39-48.
37. Schmidt A, Hori O, Brett J, Yan SD, Wautier J-L, Stern D. Cellular receptors for advanced glycation end-products: Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb. 1994; 14:1521-8.
38. Yan S, Schmidt A, Anderson G, Zhang J, Brett J, Zou Y, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end-products with their receptors/binding proteins. J Biol Chem. 1994; 269: 9889-97.
39. Wautier JL, Wautier MP, Schmidt AM, Anderson GM, Hori O, Zoukourian C, et al. Advanced glycation end-products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: A link between surface associated AGEs and diabetic complications. Proc Natl Acad Sci U S A. 1994; 91:7742-6.
40. Imani F, Horii Y, Suthanthiran M, Skolnik E, Makita Z, Sharma V, et al. Advanced glycosylation end product specific receptors on human and rat T-lymphocytes mediate synthesis of interferon-γ: Role in tissue remodeling. J Exp Med. 1993; 178:2165-72.
41. Araki N, Higashi T, Mori T, Shibayama R, Kawabe Y, Kodama T, et al. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end-products of the Maillard reaction. Eur J Biochem. 1995; 230:408-15.
42. Horiuchi S, Higashi T, Ikeda K, Saishoji T, Jinnouchi Y, Sano H, et al. Advanced glycation end-products and their recognition by macrophage and macrophage-derived cells. Diabetes. 1996; 45:S73-6.
43. Shaw S, Crabbe J. Nonspecific binding of advanced glycosylation end-products to macrophages outweighs specific receptor mediated interactions. Biochem J. 1994; 309:121-9.
44. Westwood M, McLellan A, Thornalley P. Receptor-mediated endocytic uptake of methylglyoxal-modified serum albumin. J Biol Chem. 1994; 269:32293-8.
45. Schmidt A, Yan S, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface binding proteins for AGEs. J Clin Invest. 1993; 91:2155-68.
46. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker G, Striker L. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end-products is mediated via platelet-derived growth factor. Proc Natl Acad Sci U S A. 1992; 89:2873-7.
47. Pugliese G, Pricci F, Romeo G, Pugliese F, Mene P, Giannini S, et al. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end-products via a receptor-mediated mechanism. Diabetes. 1997; 46:1881-7.
48. Schmidt A, Mora R, Rong C, Yan S, Brett J, Ramakrishnan R, et al. The endothelial cell binding site for advanced glycation end-products consists of a complex: An integral membrane protein and a lactoferrin-like polypeptide. J Biol Chem. 1994; 269:9882-8.
49. Greten J, Kreis I, Wiesel K, Stier E, Schmidt A, Stern D, et al. Receptors for advanced glycation end-products (AGE) - Expression by endothelial cells in non-diabetic uremic patients. Nephrol Dial Transplant. 1996; 11:786-90.
50. Hogan M, Cerami A, Bucala R. Advanced glycosylation end-products block the antiproliferative effect of nitric oxide. J Clin Invest. 1992; 90:1110-15.
51. Miyata T, Notoya K, Yoshida K, Horie K, Maeda K, Kurokawa K, et al. Advanced glycation end-products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol. 1997; 8:260-70.
52. Brett J, Schmidt A, Yan S, Zou Y, Weidman E, Pinsky D, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end-products in tissues. Am J Pathol. 1993; 143:1699-712.
53. 2-microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloid. J Clin Invest. 1996; 98:1088-94.
54. 2-microglobulin modified with advanced glycation end-products in the pathogenesis of hemodialysis-associated amyloidosis. J Clin Invest. 1994; 93:521-8.
55. Vlassara H, Brownlee M, Manogue K, Pasagian A, Dinarello C. Cachectin/TNF and IL-1 induced by glucose modified proteins: Role in normal tissue remodeling. Science. 1988; 240:1546-8.
56. Vlassara H, Fuh H, Donnelly T, Cybulsky M. Advanced glycation end-products promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med. 1995; 4:447-56.
57. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation end-products induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications. Proc Natl Acad Sci U S A. 1992; 89:12043-7.
58. Schmidt A, Hori O, Chen J, Li J, Crandell J, Zhang J, et al. Advanced glycation end-products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest. 1995; 96:1395-403.
59. Libby P, Hansson G. Involvement of the immune system in human atherogenesis: Current knowledge and unanswered questions. Lab Invest. 1991; 64:5-15.
60. Nguyen A, Lethais C, Zingraff J, Herbelin A, Naret C, Descamps-Latscha B. Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro with microamounts of whole blood. Kidney Int. 1985; 28:158-67.